Merdad Parsey, MD, PhD
Chief Executive Officer
Dr. Parsey joined 3-V Biosciences as its President and Chief Executive Officer in September 2010. Prior to joining 3-V, Dr. Parsey held positions of increasing responsibility at Genentech, Inc., a member of the Roche Group, most recently as Senior Group Medical Director in Genentech Research and Early Development, overseeing early clinical development in multiple therapeutic areas. Prior to his tenure with Genentech, Dr. Parsey was with Sepracor, Regeneron and Merck, Inc. He has worked on multiple development and post-marketing programs from initial human trials to NDA/BLA submissions in Respiratory, Inflammation, Virology, Neurology, Opthalmology and Gastrointestinal diseases. In addition to his work in the biotechnology and pharmaceutical industries, Dr. Parsey was the Director of Critical Care Medicine at the NYU School of Medicine. He completed his MD and PhD at the University of Maryland, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.
George Kemble, PhD
Chief Scientific Officer
Dr. Kemble joined 3-V Biosciences in August 2011 as its Chief Scientific Officer. Prior to joining 3-V, Dr. Kemble was with MedImmune, Inc., a subsidiary of Astra-Zeneca PLC, where he served as Senior Vice President of R&D and Head of Research. During his tenure, Dr. Kemble was responsible for the research and development of multiple products, including the successful launch of FluMist®, the first innovation in influenza vaccines in over 60 years. The research organization for which he was responsible included over 700 scientists in Maryland, California and Cambridge, England, with expertise in research biology, lead generation and translational science in the areas of infectious diseases, oncology, inflammatory, respiratory, autoimmune diseases, neuroscience, cardiovascular and gastrointestinal indications. Dr. Kemble began his research career as a staff scientist at Aviron, which was later acquired by MedImmune. Dr. Kemble received a BS from the University of Santa Clara and a PhD from Stanford University and did his post-doctoral training at UCSF, where he worked on a number of different human viruses.
Stephen R. Brady
Chief Business Officer
Mr. Brady has been 3-V’s Chief Business Officer since February 2011. He joined the 3-V team in 2010 as Vice President, Corporate Development, Strategy & Operations. Prior to joining the company, Mr. Brady was the Vice President of Corporate Development of Proteolix, Inc., where he had primary responsibility for Proteolix’s business development activities, resulting in the sale of the company to Onyx Pharmaceuticals, Inc. Previously, Mr. Brady served as Senior Corporate Counsel at Lexicon Pharmaceuticals, Inc., where he served in business development, communications and corporate legal capacities. Prior to his tenure with Lexicon Pharmaceuticals, Inc., Mr. Brady was a Vice President with Lazard Venture Advisors, a division of Lazard Freres & Co., LLC, and an associate in the New York and San Francisco offices of Morrison & Foerster LLP. Mr. Brady received a B.A. in English from the University of Oregon and a LL.M. from the New York University School of Law.
Edward M. Connor, Jr., MD
Chief Medical Officer
Dr. Connor joined 3-V Biosciences as the Chief Medical Officer in 2010, and is currently also Director, Office of Investigational Therapeutics, Children’s National Medical Center and a Professor of Pediatrics at the George Washington School of Medicine and Health Sciences. Previously, Dr. Connor was Executive Vice President and Chief Medical Officer at MedImmune, Inc., where he served in roles of increasing responsibility over his 14-year tenure. Prior to joining MedImmune, Dr. Connor served as the Chief of Pediatric Infectious Diseases, Director of Pediatric HIV Research, and Principal Investigator of the National Institutes of Health-funded pediatric AIDS clinical trials unit at the University of Medicine and Dentistry of New Jersey. During that time, Dr. Connor also served at a national level as Chairman of the Pediatric AIDS Clinical Trials Group and the Perinatal HIV Research Committee. Dr. Connor holds a bachelor’s degree in biology from Villanova University in Villanova, PA, and a doctorate from University of Pennsylvania School of Medicine.
Robert S. McDowell, PhD
Vice President, Research
Robert S. McDowell, PhD, joined 3-V Biosciences in 2008.
Dr. McDowell has 22 years of experience in research and development discovering small molecule drugs in cardiovascular disease, inflammation, and oncology and inflammation, with seven compounds advancing into clinical trials. Prior to joining 3-V, Dr. McDowell occupied positions of increasing responsibility at Sunesis Pharmaceuticals. As Vice President of Chemistry, he oversaw drug discovery, translational research, and manufacturing functions. Under Dr. McDowell’s leadership, the research organization earned collaboration milestones with corporate partners and successfully transitioned four partnered programs and one internal program from early discovery into development. Before joining Sunesis, Dr. McDowell was a Senior Scientist at Genentech where he developed novel strategies for peptidomimetic design that led to multiple compounds advancing into development. Dr. McDowell also led the Structural Chemistry group at Axys Pharmaceuticals and contributed to the Cathepsin K program currently in Phase 3 trials by Merck. Dr. McDowell has authored over 40 peer-reviewed manuscripts and is an inventor on over 20 issued US patents. Dr. McDowell holds a PhD in Chemistry from the University of California at Berkeley.